Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

ValiRx (VAL)

Price 0.80p on 20-01-2025 at 16:35:03
Change 0.00p 0%
Buy 0.85p
Sell 0.75p
Buy / Sell VAL Shares
Last Trade: Buy 188.00 at 0.85p
Day's Volume: 4,596,971
Last Close: 0.80p
Open: 0.80p
ISIN: GB00BLH13C52
Day's Range 0.775p - 0.80p
52wk Range: 0.625p - 5.15p
Market Capitalisation: £3m
VWAP: 0.798819p
Shares in Issue: 374m

Recent Trades History ValiRx (VAL)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 188 0.85p Ordinary
16:18:09 - 20-Jan-25
Sell* 54,166 0.788p Ordinary
15:41:06 - 20-Jan-25
Buy* 68,000 0.82p Ordinary
15:08:22 - 20-Jan-25
Buy* 120,493 0.82p Ordinary
14:59:44 - 20-Jan-25
Buy* 120,793 0.82p Ordinary
14:04:24 - 20-Jan-25
Sell* 100,000 0.788p Ordinary
14:00:34 - 20-Jan-25
Buy* 105,359 0.821p Ordinary
13:39:43 - 20-Jan-25
Sell* 344,023 0.786p Ordinary
13:07:25 - 20-Jan-25
Buy* 40,000 0.825p Ordinary
13:05:23 - 20-Jan-25
Sell* 40,000 0.786p Ordinary
11:58:57 - 20-Jan-25

Share Price History for ValiRx

Time period:
to
Date Open High Low Close Volume

Share News for ValiRx

AIM WINNERS & LOSERS: Strong 2024 for Quadrise and Rosebank

31st Dec 2024 10:58

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday. Read More

ValiRx extends TheoremRx exclusivity period to final May 31 deadline

31st Dec 2024 10:58

(Alliance News) - ValiRx PLC on Tuesday said it has extended the exclusivity period for a proposed sub-license agreement with TheoremRx Inc for its VAL201 therapeutic candidate, setting a final deadline of May 31. Read More

IN BRIEF: ValiRx extends Ambrose Healthcare exclusivity agreement

20th Nov 2024 18:09

ValiRx PLC - Essex, England-based life sciences company - Says subsidiary ValiSeek Ltd has granted a six-month extension to Ambrose Healthcare Ltd offered under the exclusive option agreement inked in December 2023 to execute an exclusive sub-license of ValiSeek's VAL401 asset. Ambrose Healthcare now has a further six-month period during which it can choose to exercise the option. VAL401 is in development for the treatment of pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Read More

ValiRX adds to streak of deals with cancer cell test materials win

19th Nov 2024 11:39

(Alliance News) - ValiRX PLC announced on Tuesday it will provide more cancer cell detection materials to UK biotech firm Amply Discovery Ltd. Read More

AIM WINNERS & LOSERS: Woodbois subscription raises over GBP1 million

19th Nov 2024 10:39

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday. Read More

FTSE 100 Latest
Value8,520.54
Change15.32

Login to your account

Forgot Password?

Not Registered